Focused On-demand Library for AN1-type zinc finger protein 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O76080

UPID:

ZFAN5_HUMAN

Alternative names:

Zinc finger A20 domain-containing protein 2; Zinc finger protein 216

Alternative UPACC:

O76080; A8K484

Background:

AN1-type zinc finger protein 5, also known as Zinc finger A20 domain-containing protein 2 or Zinc finger protein 216, plays a crucial role in protein degradation through the ubiquitin-proteasome system. It anchors ubiquitinated proteins to the proteasome, regulating muscle atrophy, NF-kappa-B activation, and apoptosis. It inhibits NF-kappa-B activation induced by RIPK1, TRAF6, TNF, IL-1, and TLR4, and sensitizes cells to TNF-induced apoptosis. It also acts as an inhibitory factor for osteoclast differentiation.

Therapeutic significance:

Understanding the role of AN1-type zinc finger protein 5 could open doors to potential therapeutic strategies.